Advertisement
Advertisement
MDGL
Madrigal Pharmaceuticals, Inc. Common Stock
538.71
USDSponsored
-1.32
-0.24%
Sep 01, 15:59 UTC -4
Closed
Pre-Market
526.50
-12.21
-2.27%
MDGL Earnings Reports
Positive Surprise Ratio
MDGL beat 24 of 43 last estimates.
56%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$412.39M
/-$0.92
Implied change from Q2 26 (Revenue/ EPS)
+13.22%
/-53.77%
Implied change from Q3 25 (Revenue/ EPS)
+43.56%
/-81.45%
Madrigal Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Jul 30, 2026, MDGL reported earnings of -1.99 USD per share (EPS) for Q2 26, beating the estimate of -2.61 USD, resulting in a 23.96% surprise. Revenue reached 364.25 million, compared to an expected 360.24 million, with a 1.11% difference. The market reacted with a -9.83% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of -0.92 USD, with revenue projected to reach 412.39 million USD, implying an decrease of -53.77% EPS, and increase of 13.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
BioLineRX Ltd
Report Date
Aug 31, 2026 For Q2 26
Estimate
-Actual
-$0.77
Surprise
-
FAQ
What were Madrigal Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Madrigal Pharmaceuticals, Inc. Common Stock reported EPS of -$1.99, beating estimates by 23.96%, and revenue of $364.25M, 1.11% above expectations.
How did the market react to Madrigal Pharmaceuticals, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -9.83%, changed from $546.88 before the earnings release to $493.11 the day after.
When is Madrigal Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Madrigal Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 12
analysts, Madrigal Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.92 and revenue of $412.39M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement